ScholarIQanswers from OpenAlex & ORCID
Wendy M. Blumenschein
ResearcherPublications, citations & collaboration network
Wendy M. Blumenschein is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Wendy M. Blumenschein have?
ScholarIQindexed works
Wendy M. Blumenschein has 95 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Wendy M. Blumenschein have?
ScholarIQcitation count
Wendy M. Blumenschein has 20,228 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Wendy M. Blumenschein?
ScholarIQh-index
Wendy M. Blumenschein has an h-index of 33 in OpenAlex.
What is the i10-index of Wendy M. Blumenschein?
ScholarIQi10-index
Wendy M. Blumenschein has an i10-index of 42 in OpenAlex.
What is the ORCID of Wendy M. Blumenschein?
ScholarIQorcid
The ORCID for Wendy M. Blumenschein is on the source record.
What is the OpenAlex record for Wendy M. Blumenschein?
ScholarIQopenalex
The OpenAlex for Wendy M. Blumenschein is on the source record.
What are the most-cited papers on Wendy M. Blumenschein?
ScholarIQmost cited works
IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2–dependent mechanisms with implications for psoriasis pathogenesis
Jason R. Chan, Wendy M. Blumenschein, Erin Murphy, Caroline Diveu, Maria Wiekowski, Susan J. Abbondanzo, Linda Lucian, Richard Geissler, Scott J. Brodie, Alexa B. Kimball, Daniel M. Gorman, Kathleen M. Smith, René de Waal Malefyt, Robert A. Kastelein, Terrill K. McClanahan, Edward P. Bowman
Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study
Giuseppe Giaccone, Chul Kim, Jillian Thompson, Colleen McGuire, Bhaskar Kallakury, Joeffrey Chahine, Maria A. Manning, Robin Mogg, Wendy M. Blumenschein, Ming Tan, Deepa S. Subramaniam, Stephen V. Liu, Ian M. Kaplan, Justine N. McCutcheon
T‐cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death‐ligand 1 expression in patients with soft tissue sarcomas
Seth M. Pollack, Qianchuan He, Jennifer H. Yearley, Ryan Emerson, Marissa Vignali, Yuzheng Zhang, Mary W. Redman, Kelsey K. Baker, Sara J. Cooper, Bailey Donahue, Elizabeth T. Loggers, Lee D. Cranmer, Matthew B. Spraker, Yongwoo David Seo, Venu G. Pillarisetty, Robert W. Ricciotti, Benjamin Hoch, Terrill K. McClanahan, Erin Murphy, Wendy M. Blumenschein, Steven M. Townson, Sharon Benzeno, Stanley R. Riddell, Robin L. Jones
Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma
Lakshmi Nayak, Annette M. Molinaro, Katherine B. Peters, Jennifer Clarke, Justin T. Jordan, John de Groot, Leia Nghiemphu, Thomas Kaley, Howard Colman, Christine McCluskey, Sarah Gaffey, Timothy R. Smith, David J. Coté, Mariano Severgnini, Jennifer H. Yearley, Qing Zhao, Wendy M. Blumenschein, Dan G. Duda, Alona Muzikansky, Rakesh K. Jain, Patrick Y. Wen, David A. Reardon